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Abstract. Effective verification and validation are central to medical 
device software development and are essential for regulatory approval. 
Although guidance is available in multiple standards in the medical 
device software domain, it is difficult for the manufacturer to implement 
as there is no consolidated view of this information. Likewise, the 
standards and guidance documents do not consider process 
improvement initiatives. This paper assists in relation to both these 
aspects and introduces the development of processes for verification 
and validation in the medical device domain. 
Keywords: Medical device standards, Medical device software 
verification and validation, Medical device software process assessment 
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1 Introduction 
Verification and Validation (V&V) activities are important activities in the 
software development lifecycle and consume up to 50% of project 
development time [1], [2] and up to 50% of the total cost [3]. While both V&V 
play a key role in software development, there is a level of ambiguity in the 
use of both of these terms.  This is evident from the difference in the definition 
of these terms in the literatures [4], [5] and [6].  
 
When developing safety-critical software it is imperative to have software 
development practices which incorporate effective V&V activities.  In this 
context V&V are addressed by numerous standards for both generic and 
safety-critical software development which include specific medical device 
standards.  
 
The National Institute of Standards and Technology performed a study, 
indicating that software defects cost the U.S. economy in the region of $59.5 
billion a year [7]. The study also indicates that better testing could detect and 
  
remove defects early in the development process and reduce the cost by 
more than a third [7]. However, there are challenges in the implementation of 
V&V in the context of general software development and these challenges are 
even greater in safety-critical domains. The requirements put forth by the 
regulatory bodies stress the need for supporting documentation and it can be 
challenging to satisfy these regulatory requirements and meet the pressures 
of the market at the same time.  
2  Verification & Validation in Generic Software Development   
Two important reference models which are widely used in the context of 
software process improvement are the Capability Maturity Model® Integrated 
(CMMI
®
) [8] and ISO/IEC ISO/IEC 15504-5:2006  [9].  When considering 




 recommends a lifecycle approach for V&V activities. It defines 
verification as ―Confirmation that work products properly reflect the 
requirements specified for them‖.  In other words, verification ensures that 
―you built it right‖ and validation is ―Confirmation that the product, as provided 
(or as it will be provided), will fulfill its intended use‖. In this context, validation 
ensures that ‗you built the right thing‘. The V&V processes are part of the 
engineering processes category and both are level 3 process areas in the 
staged model. The model also provides guidance in terms of examples of 
methods such as peer reviews; statement coverage testing and branch 
coverage testing that could be performed. The validation process area 
incrementally validates products against the customer‘s needs. Validation 
may be performed in the operational environment or simulated operational 
environment. Coordination with the customer in relation to validation 
requirements is an important element of this process area. The scope of the 
validation process area includes validation of products, product components, 
selected intermediate work products, and processes. These validated 
elements may often require re-verification and re-validation. 
 
In ISO/IEC 15504-5:2006 V&V are two distinct processes and are part of the 
supporting lifecycle process group. Both of these processes are based on the 
respective lifecycle processes in ISO/IEC 12207 AMD1 [10]. In ISO/IEC 
15504-5, the purpose of the verification process is to confirm that each 
software work product and/or service of a process or project properly reflects 
the specified requirements. The tasks pertaining to verification include: 
development of a verification strategy, development of criteria for verification, 
performing the activity of verification, determination of actions based on 
verification results and making the results available to the stakeholders. 
Industry experience indicates that V&V activities typically consume about 30-
50% of development budgets [11]. CMMI
®
 and ISO/IEC15504-5 are not 
prescriptive when it comes to methods and tools to be used for V&V. Rather it 
is left to the discretion of the user to select and apply methods. Though 
CMMI
®
, considers validation and verification, it is still rather modest in its 
focus on these areas compared to other elements of the development 
processes [12].  
3 Verification & Validation for Safety-Critical Software 
Development   
Software can be a critical element of complex, potentially dangerous products 
such as weapons systems, aerospace systems and medical devices. These 
are critical because failure can result in loss of life, significant environmental 
damage, and major financial loss [13]. It has also been found that there is a 
relationship between the increasing occurrence of system accidents and the 
increasing usage of software [14]. In these circumstances these products are 
required to meet a very high-level of reliability, security, and performance. 
Therefore, ensuring that such systems meet their predefined requirements 
and that they perform as expected is an essential and often challenging issue 
[15].   
 
Within the safety-critical software arena, different standards/certifications are 
available for different industries. These include the MIL-STD-498 [16] for 
military applications, DO-178B [23] for Aerospace, and Automotive SPICE 
and ISO 26262 [17] in the Automotive industry.  IEC 60880 [18] describes the 
European standards for the certification of nuclear power generating software.  
IEC 61508 [19] describes a general-purpose hierarchy of safety-critical 
development methodologies that has been applied to a variety of domains 
ranging from medical instrumentation to electronic switching of passenger 
railways. Though these standards address V&V in sufficient detail, their role is 
not to address process improvement. In addition, there are some [20] who 
consider that a CMMI
®
 V&V assessment inadequate when dealing with 
safety-critical software, and they propose a new framework for V&V 
assessment, focused on safety-criticality. This framework is defined through 
integrating safety standards with the V&V process areas of the CMMI
®
 and 
the ISO 9001 standard [21]. 
 
The following are some of the attributes of safety standards: (1) Product 
versus process (2) Safety management agents (3) Risk assessment (4) 
Integrity levels (5) Design safety and (6) Assurance techniques [22]. Based on 
these criteria, we decided to use DO-178B and the Automotive SPICE as part 
of our research for developing V&V processes for the medical device software 
domain. Automotive SPICE has been derived from ISO/IEC 15504-5.  This 
was of particular relevance as it was developed for a safety-critical domain to 
facilitate process assessment and improvement.  
Therefore, existing software process reference models need to be adapted 
and extended to meet the specific requirements of medical device software 
development which is safety-critical in nature.  
  
4 Research Approach and Outcomes 
The research undertaken involved a number of key stages:  
1. The V&V processes were reviewed in detail and consideration was 
given to how they were addressed by generic software development 
standards and process improvement reference models, which 
included ISO/IEC 12207, ISO/IEC 15504-5 and CMMI
®
.  
2.  A literature review of V&V was performed in terms of safety-critical 
software development. This included a review of the V&V processes 
addressed by safety-critical software development standards such as 
DO-178B and Automotive SPICE [24]. 
3. A literature review and analysis was also performed in relation to 
medical device software V&V. This incorporated the Food and Drug 
Administration (FDA) guidelines for Software Validation (FDA GPSV) 
[25], the Medical Device Directive (MDD) 1993/42/EEC [26] and 
amendment 2007/47/EC [27]  ,ISO/IEC 62304 [28],  ISO/IEC 13485 
[29] and  ISO/IEC 14971 [30].  
4.  Based on this analysis we defined a set of processes for V&V for 
medical device software development. The processes were assigned 
a Process ID, Process Name, Process Purpose, Process Outcomes 
and a set of Specific Practices.  Guidance in the implementation of 
these specific practices is provided through a set of sub-practices and 
notes.  These processes were developed as part of the Medi SPICE 
[41].  
4.1 Regulatory Nature of the Medical Device Domain    
Studies in the medical device industry [31], [32], point to the fact that software 
is one of the most critical factors for cutting edge products and the role 
software plays is predicted to continue to increase [32]. It is also expected 
that, by 2015, the research and development investment in software in this 
area will increase from 25% of the overall budget in 2002, to 33% [32]. 
 
However, as the role of software in the medical device domain increases, so 
do the number of failures which arise due to software defects. An analysis of 
medical device recalls by the FDA in 1996 [33] found that software was 
increasingly responsible for product recalls. This continues to be the case and 
in the period the 1
st
 January 2010 to 1
st 
January 2011 the FDA recorded 80 
medical device recalls and state software as the cause [46].  A German 
survey on medical device recalls indicated that software was the top cause for 
risks related to construction and design defects of medical device products. 
This analysis, from June 2006, showed that 21% of the medical device design 
failures were caused by software defects. This was an increasing trend, as 
the figures from November 2005 showed software was responsible for 17% of 
construction and design defects [34]. 
 
Due to the safety-critical nature of medical devices, medical device 
companies who wish to sell their products must comply with the regulatory 
requirements of the respective countries where they plan to market them. 
Medical devices can only be sold in the US if they comply with the FDA 
regulations [35], whereby a quality system needs to be in place that complies 
with the FDA Regulations 21 CFR Part 820, Quality System Regulation (QSR) 
[36]. In order to sell devices the manufacturer not only has to prove safety and 
effectiveness, but also has to demonstrate that the design and development 
of the device including the software complies with the FDA regulations. The 
―Guidance for the Content of Premarket Submissions for Software Contained 
in Medical Devices‖ document [37] details these requirements.  Though the 
regulatory bodies, such as the FDA provide guidance documents, they do not 
dictate that a particular method must be used [38]. The quality system 
process itself is designed by the medical device manufactures and the quality 
system process needs to ensure that the manufacturer is designing and 
building a quality product. The difficult part is that the manufacturer has to 
provide evidence to the FDA inspectors that the. correct processes have been 
followed [35 . 
 
 
In order to achieve standardization of expectations and for better guidance for 
implementation by manufacturers, the FDA Center for Devices and 
Radiological Health (CDRH) has published guidance documents which 
include risk-based activities to be performed during software validation [25], 
pre-market submission [37] and when using off-the-shelf software in a medical 
device [39].  Although the CDRH guidance documents provide information on 
which software activities should be performed, they do not enforce any 
specific method for performing these activities. The result is that the medical 
device manufacturers could fail to comply with the expected requirements.  
 
Within the medical device industry a decision was initially made to recognize 
ISO/IEC 12207:1995 (a general software engineering lifecycle process 
standard) as being suitable for general medical device software development 
[10].  However, upon careful examination of ISO/IEC 12207, the Association 
for the Advancement of Medical Instrumentation (AAMI) software committee 
decided it was necessary to create a new standard specifically for medical 
device software development. The AAMI used ISO/IEC 12207:1995 as the 
foundation for their new standard ―AAMI SW68, Medical device software – 
Software lifecycle processes‖ [38]. In 2006, a new standard AAMI/IEC 62304 
[28] was released that was based on the AAMI SW68 standard.  
In order to sell medical devices within the Europe Union (EU) the CE mark is 
required. To achieve the CE mark compliance is required with the Medical 
Device Directive (MDD) (1993/42/EEC) and amendment MDD (2007/47/EC), 
In-Vitro Diagnostic Directive (IVDD) [44] and the Active Implantable Medical 
Device Directive (AIMDD) [45] depending on the type of medical device being 
submitted. As stated in the latest amendment to the MDD, Section 1 (g) of 
  
MDD (2007/47/EC) ―For devices which incorporate software or which are 
medical software in themselves, the software must be validated according to 
the state of the art taking into account the principles of development lifecycle, 
risk management, validation and verification‖. ―State of the Art‖ is used here to 
mean what is generally accepted as good practice. Since this requirement 
was introduced, developers must now validate the software be it integrated or 
standalone, regardless of device class.  IEC 62304 and its aligned standards 
are often seen as a good place to start when validating software.   Whilst 
these standards are generally accepted and are harmonised under the MDD 
they do contain omissions which make them difficult to apply to standalone 
software as an active medical device.  As we had observed from our research 
this is exemplified by IEC 62304 where there is no provision within the 
standard to validate the system elements of standalone software. 
 
While there are numerous standards in the medical device domain they are 
oriented towards achieving regulatory compliance.  As a result the focus of 
medical device software development is compliance rather than process 
improvement.   To address this Medi SPICE is being developed. The objective 
of Medi SPICE is to provide a process assessment and improvement model 
which is domain specific to medical device software development and 
incorporates regulatory compliance. Medi SPICE will also enable the 
harmonization of different standards in the medical device software 
development domain, thus bringing best practices available in multiple 
standards into a single framework which will aid manufacturers in the 
implementation of their requirements as well as in their process improvement 
exercise.  The results of a Medi SPICE assessment may be used to indicate 
the state of a medical device suppliers software practices in relation to the 
regulatory requirements of the industry, and identify areas for process 
improvement. The results of these assessments may also be used as a 
criterion for supplier selection. The authors believe that, with the publication of 
the Medi SPICE more specific guidance will be available for the basis of 
process design and assessment in the medical device industry [41].  
4.2 Verification & Validation in Medi SPICE  
Based on our research which comprised of an extensive literature review and 
comparative analysis of standards in the medical device and other safety-
critical domains, we arrived at the following findings, which were incorporated 
into the definition of the processes related to V&V in Medi SPICE: 
a. From the literature review and comparison across other standards 
and models, it became clear that the terms V&V are frequently used 
interchangeably. The FDA guidelines distinguish between verification 
and validation. Though the FDA is clear on the definition part, 
sections 4, 5 and 6 of the FDA GPSV, which deals with operational 
activities, still use the term validation only and no reference is made 
to verification. Guidance on differentiating between V&V activities with 
respect to the different engineering activities/work products should be 
in place.  The amendment 2007/47/EC to the MDD stresses the 
importance validation plays and the need for state of the art validation 
and verification  
b. Verification is not addressed as a separate process in IEC 62304 and 
verification practices are integrated into other engineering processes. 
Validation is considered a systems level process and outside the 
scope of IEC 62304 even when the system consists entirely of 
software.  
c. Automotive SPICE has V&V criteria and V&V records as outputs in its 
processes. The ISO/IEC 15504-5 does not go to this level of detail.  
d. The IEEE Standards for Software V&V state that classical 
Independent Verification & Validation (IV&V) is generally required for 
the development of software systems deemed ―critical‖, i.e., those 
which can result in loss of life, mission or significant social or financial 
loss [42]. Independence is an important factor addressed by DO-
178B. The degree of independence is also addressed in ISO/IEC 
15504-5 and Automotive SPICE. The FDA GPSV Sec 4.9 does 
address independence and leaves it to the discretion of device 
manufacturers as to how this is to be achieved. Independence is not 
addressed as part of IEC 62304 and it assumes that it is taken care of 
by/through ISO 13485. Therefore, in Medi SPICE we placed a 
particular focus on the clarity of independence in the verification and 
validation processes.   
e. Software developed for medical devices concerns itself with obtaining 
regulatory approval as opposed to improving processes to achieve 
more efficient software development [40]. Models like CMMI
®
 and 
ISO/IEC 15504-5 have separate process areas for verification and 
validation. A separate process area for critical processes like V&V 
enable organizations to understand their strengths and weaknesses 
in a detailed manner and can provide help when embarking on 
process improvement initiatives.   
 
From our analysis of the relevant literature regarding V&V and through the 
comparative analysis of process improvement models and standards, our goal 
was to determine best practice in this area and to facilitate process 
improvement.  Our objective was also to satisfy the requirements of the 
relevant medical device standards which include the FDA GPSV, MDD, 
ISO/IEC 13485, IEC 62304, IEC TR 80002-1 [43] and ISO14971. Having 
established these elements, it was imperative we incorporate them into Medi 
SPICE. To achieve this we developed the following Medi SPICE processes 
with a particular emphasis on verification and validation:  
1. Software Construction  
2. Software Integration 
3. Software Testing  




As discussed in Section 4, our objective was to incorporate the relevant 
standards and the most effective elements of process improvement models 
into a common framework specifically designed for the medical device 
software domain, Medi SPICE. 
 
Unlike ISO/IEC 15504-5, where there is no requirement for the classification 
of outcomes and processes based on safety, this was an important element 
which had to be included in Medi SPICE. We therefore utilized the 
classification schema provided by IEC 62304, which is used to associate the 
outcomes and specific practices with the safety level of the software for which 
the practices are applicable.  While we based the practices on the 
ISO/IEC15504-5, our analysis of standards in similar safety-critical domains 
highlighted that it would be beneficial to use Automotive SPICE as our 
reference, as it is has been developed to meet the specific requirements of 
safety-critical software development. As a result of the findings from our 
research, we have included V&V as separate process areas in Medi SPICE. 
The validation process includes many of the recommendations that were 
produced as part of this research. 
 
Risk management is an integral part of medical device software development. 
In this context the relevant standards for medical device development are ISO 
14971 and IEC 62304. IEC/TR 80002-1 provides specific guidance as to how 
these two standards can be combined to address risk with regard to medical 
device software development. The requirements of V&V as required by these 
standards have been addressed in the five processes listed above.  
4.3 Summary of Verification & Validation related Processes in Medi SPICE  
For the purpose of this paper, we use the Software Testing (ENG.8) process 
in Medi SPICE as an example. This process relates to the IEC 62304 
Software System Testing activity which has five tasks. As an outcome of our 
analysis, specific practices (1 to 10) were defined for the Software Testing 
Process. The practices and how they map to relevant medical device 







Table 1: Mapping ISO/IEC 62304 Tasks to Medi SPICE practices   
IEC 62304 
Reference 
Sub Task / Clause Medi SPICE 
Reference 
Medi SPICE Reference 
5.7.1 Establish tests for 
software 
requirements 
ENG.8.SP1 Develop software test 
strategy 
    ENG.8.SP1.1 Establish a set of tests 
    ENG.8.SP2 Develop test 
specification for software 
test 
    ENG.8.SP4 Test the integrated 
software 
5.7.2 Use software 
problem resolution 
process 
ENG.8.SP5 Record the anomalies 
5.7.3 Retest after changes ENG.8.SP9 Develop regression test 
strategy and perform 
regression testing 
5.7.4 Verify software 
system testing 
ENG.8.SP3 Verify test specification 
for software test 
    ENG.8.SP7 Verify software testing 
5.7.5 Software system test 
record contents 
ENG.8.SP6 Record results of 
software test 
    ENG.8 SP8 Ensure consistency and 
bilateral traceability 
    ENG.8.SP10 Conduct risk 
management activities  
 
 
Against the five tasks that the IEC 62304 provides, the Medi SPICE Software 
Testing Process has nine specific practices and one sub practice. In line with 
the good practice of ensuring traceability at each engineering activity level as 
observed in ISO/IEC 15504-5, Medi SPICE also focuses on using traceability 
in each engineering activity as it is very important from a verification 
perspective. In addition, to the specific practices a single sub-practice, 
additional implementation guidance is provided through 10 notes in the 
Software Testing Process.  It may be noted from Table 1 that a specific 
practice – Conduct risk control activities has been added as part of the model. 
We are thus providing guidance through Medi SPICE on risk management 
activities in line the ISO 14971, which requires verification of the 
implementation of risk control, as well as verification of the reduction of risk 
through adopting risk control mechanisms.   
 
  
Table 2, outlines how we have addressed some of the typical software testing 
tasks, with reference to the FDA GPSV guidance document. 
 
Table 2: Mapping FDA Typical tasks to Medi SPICE 
FDA Typical Tasks  Medi SPICE Reference 
Test Planning  Software Construction 
Functional test case identification Software Construction 
Traceability analysis Software Construction,  
Software Integration,  
Software Testing  
Unit (module) test execution Software Construction 
Integration test execution Software Integration 
Functional test execution Software Integration 
System test execution Software Testing 
Error evaluation/resolution Software Testing  
Final Test Report  Software Testing 
 
 
The requirements of FDA GPSV are directly addressed by Medi SPICE as 
can be observed from the mapping. Further, it needs to be noted that the task 
of Acceptance test execution is not addressed by Medi SPICE as part of 
software engineering processes. This is in line with the Automotive SPICE as 
well as ISO/IEC 15504-5, where acceptance testing is part of the acquisition 
group of processes. 
5 Conclusions and Future Work  
Further to the definition of a set of process areas and the associated practices 
related to V&V, the processes should be piloted in organizations within the 
medical device software development industry. Based on the results 
observed, the processes should be evaluated and continuously improved 
based upon feedback from the medical device software development industry. 
Additionally, as V&V absorbs a significant amount of project time, further 
research will be performed out on practices, which could bring in reduction in 
cycle time for V&V activities but without compromising quality and safety 
features of the products being developed.  
 
Globalization of software development has led to distributed teams working on 
the same product in different locations. Understanding the challenges in 
globally distributed V&V in the context of medical device software 
development and what additional practices could aid practitioners in such 
cases. These practices could then become notes or sub-practices in further 
versions of Medi SPICE.  
 
As medical device manufacturers outsource their medical device software 
development, it would be worthwhile to examine: (a) what could be drivers in 
outsourcing V&V activities to a third party. (b) if outsourcing of medical device 
software development is performed, will V&V still be done internally? (c) What   
risks should be considered and practices should be included in a reference 
model for medical device software development from a V&V perspective for 
3rd party software (COTS) or where certain activities are outsourced? 
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